Compare BFS & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFS | ODTX |
|---|---|---|
| Founded | 1993 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 902.2M | 875.1M |
| IPO Year | 1996 | 2025 |
| Metric | BFS | ODTX |
|---|---|---|
| Price | $34.76 | $20.69 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $44.00 | N/A |
| AVG Volume (30 Days) | 86.1K | ★ 173.5K |
| Earning Date | 05-11-2026 | N/A |
| Dividend Yield | ★ 6.92% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.50 | N/A |
| Revenue | ★ $289,843,000.00 | N/A |
| Revenue This Year | $0.30 | N/A |
| Revenue Next Year | $5.67 | N/A |
| P/E Ratio | $70.00 | ★ N/A |
| Revenue Growth | ★ 7.81 | N/A |
| 52 Week Low | $29.16 | $15.10 |
| 52 Week High | $38.42 | $23.08 |
| Indicator | BFS | ODTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.88 | 56.19 |
| Support Level | $32.60 | $15.10 |
| Resistance Level | $34.99 | N/A |
| Average True Range (ATR) | 0.92 | 1.74 |
| MACD | 0.08 | 0.15 |
| Stochastic Oscillator | 59.15 | 56.51 |
Saul Centers Inc is a self-managed real estate investment trust which invests in, operates and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: Shopping Centers segment, which contribute the maximum portion of total revenue; and mixed-use properties.Mixed-Use Properties segment include office, retail and multi-family residential use.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.